Openbookopenbook
Equity
TBPH
+0.0 · +0.00%
USD · NASDAQ

Theravance Biopharma Inc(TBPH) Stock Analysis | Healthcare

USD --+0.00%
Reward74High
Risk16Low
75%Data
Strong 52% profit margin · Revenue down 21% YoY
Quality Compounder
Market Cap:885.21M
ⓘ
Reward Rating
74
High
Reward Assessment
75% data coverage
Top 10% of stocksView factors
ⓘ
Risk Rating
16
Low
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on TBPH to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for TBPH, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $17.67.

What is Theravance Biopharma Inc?

, a biopharmaceutical company, develops and commercializes medicines in the United States.

TBPH · Verdict

Strong reward · low risk

TBPH scores well on valuation and volatility with no major weaknesses flagged in the model.

Based on 88% data coverage

TBPH · Verdict

What’s working & what to watch

Strengths 6

  • Valuation98/100

    P/E 5.6× · PEG 0.01

  • Volatility95/100

    Top decile vs peers

  • Profitability90/100

    99% net margin · 21% ROE

  • Balance sheet85/100

    Interest covered 53.5×

  • Growth72/100

    Rev +27.9% CAGR · earnings -50.5%

  • Cash flow72/100

    222% free-cash-flow margin

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Theravance Biopharma Inc?

, a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 885.21M, and a P/E ratio of 16.4x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (74)

The scoring profile indicates a strong reward potential, driven primarily by valuation and profitability. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

ANLSmall Cap / 882M market cap
Adlai Nortye Ltd. American Depositary Shares
Compare
DBVTSmall Cap / 881M market cap
DBV Technologies
Compare
SGPSmall Cap / 876M market cap
SpyGlass Pharma, Inc.
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap885.21M
P/E Ratio16.3942
Dividend YieldN/A
Beta0.246
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.